Advertisement

International Journal of Clinical Pharmacy

, Volume 38, Issue 2, pp 421–428 | Cite as

Study on daptomycin use and implementation of an antimicrobial stewardship program

  • Camille CastelEmail author
  • Arnaud de La Blanchardière
  • Jocelyn Michon
  • Vincent Cattoir
  • Guillaume Saint-Lorant
Research Article
First Online:

Abstract

Background Treatment of Gram-positive pathogens remains a major health issue due to the presence of methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-Resistant Enterococcus spp. Daptomycin offers an alternative after therapeutic failure using glycopeptides. Yet its use requires strict control given its financial impact and environmental risks. Since 2014, the use of daptomycin within our hospital has intensified, occasionally outside the scope of its approved indications. Objectives: The aim of this study is to analyze the appropriateness of daptomycin prescriptions. Setting This work was conducted in a 1500-bed University Hospital. Method A descriptive retrospective study was conducted from November 2013 to July 2014. All patients having received at least 2 days of treatment were included. Analysis of the appropriateness of daptomycin prescriptions was conducted by a multidisciplinary team comprised of infectious diseases specialists, pharmacists and a microbiologist. The appropriateness of daptomycin prescriptions was established based on Infectious Diseases Society of America recommendations published in 2011. Main outcome measures: The indicators chosen to determine appropriateness of prescription were: treatment indication, prescribed dose and other antibiotics associated with the daptomycin prescription. Results 19 patients (14 men/5 women) were included. Observed indications were: bone and joint infection (n = 6; 32 %), infectious endocarditis (n = 5; 26 %), bacteremia (n = 5; 26 %) and complicated skin and soft tissue infection (n = 3; 16 %). Identified pathogens were: MRSA (n = 14; 74 %), methicillin-resistant coagulase-negative Staphylococcus (n = 4; 21 %) and Streptococcus mitis (n = 1; 5 %). Daptomycin was prescribed as first-line treatment in 32 % of cases (n = 6). The mean dosage was 9 mg/kg/day (5–11 mg/kg/day) for a mean duration of 11 days (2; 55 days). Clinical success was observed in 42 % of cases (n = 8). Appropriateness for daptomycin use was only established for 15 % of prescriptions (n = 3). Conclusion Faced with a lack of recent recommendations on the subject, our multidisciplinary team issued a local consensus, defining the indications and dosage modalities for this reserve antibiotic. This multidisciplinary approach enables improved use of recent anti-MRSA drugs

Keywords

Antimicrobial stewardship Bone and joint infection Daptomycin Endocarditis France Prescribing audit 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

The authors thank the following pharmacists for their contribution to data collection: Morgane Bonnet, Angélique Cotteau-Leroy, Marie-Christine Douet, Thierry Henon, Dominique Levêque, Isabelle Poujol and Isabelle Tiret.

Funding

The authors received no funding for this study.

Conflicts of interest

The authors declare they have no conflict of interest concerning this article

References

  1. 1.
    Lushniak BD. Antibiotic resistance: a public health crisis. Public Health Rep. 2014;129(4):314–6.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Enoch DA, Bygott JM, Daly ML, Karas JA. Daptomycin. J Infect. 2007;55(3):205–13.CrossRefPubMedGoogle Scholar
  3. 3.
    French National Agency for Drug and Health Safety (France). Transparency Committee: daptomycin. Haute Autorité de santé; 2006 Oct. France. http://www.hassante.fr/portail/upload/docs/application/pdf/2009-01/ct_2927_cubicine_ang_2009-01-15_11-30-23_417.pdf. Accessed Feb 2014
  4. 4.
    Arbeit RD, Maki D, Tally FP, Capanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38(12):1673–81.CrossRefPubMedGoogle Scholar
  5. 5.
    Quist SR, Fierlbeck G, Seaton RA, Loeffler J, Chaves RL. Comparative randomized clinical trial against glycopeptides supports the uses of daptomycin as first-line treatment of complicated skin and soft-tissue infections. Int J Antimicrob Agents. 2012;39(1):90–1.CrossRefPubMedGoogle Scholar
  6. 6.
    Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653–65.CrossRefPubMedGoogle Scholar
  7. 7.
    Boucher HW, Sakoulas G. Perspectives on daptomycin resistance with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis. 2007;45(5):601–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Van Hal SJ, Paterson L, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteremia in a daptomycin naïve patient, a review of the literature. Eur J Clin Microbiol Dis. 2011;30(5):603–10.CrossRefGoogle Scholar
  9. 9.
    Humphries RM, Pollett S, Saoulais G. A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev. 2013;26(4):759–80.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Cui L, Tominaga E, Neoh HM, Himaratsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50(3):1079–82.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Tenover FC, Sinner SW, Segal RE, Huang V, Alexandre SS, McGowan JE Jr, et al. Characterization of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy. Int J Antimicrob Agents. 2009;33(6):564–8.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Daptomycin: a review 4 years after first approval. Pharmacology. 2008;81(2):79–91.CrossRefPubMedGoogle Scholar
  13. 13.
    He W, Zhang Y, Chen H, Zhao C, Wang H. Efficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized trials. J Antimicrob Chemother. 2014;69(12):3181–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Jones RN, Barry AL. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrob Agents Chemother. 1987;31(4):625–9.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Murray KP, Zhao JJ, Davis SL, Kullar R, Kaye KS, Lephart P, et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. Clin Infect Dis. 2013;56(11):1562–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Montange D, Berthier F, Leclerc G, Serre A, Jeunet L, Berard M, et al. Penetration of daptomycin into bone and synovial fluid in joint replacement. Antimicrob Agents Chemother. 2014;58(7):3991–6.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    French National Agency for Drug and Health Safety (France). Clinical Practice Guidelines: Antibiotic therapy and prevention of bacterial resistance in healthcare organization. Haute Autorité de Santé; 2008 Apr. France. http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-03/antibiotic_therapy_and_prevention_of_bacterial_resistance_guidelines.pdf. Accessed March 2014
  18. 18.
    Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):285–92.CrossRefPubMedGoogle Scholar
  19. 19.
    French National Agency for Drug and Health Safety (France). Caractérisation des antibiotiques considérés comme « critiques». ANSM. 2013 Nov. France. http://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Les-antibiotiques-consideres-comme-critiques-premieres-reflexions-sur-leur-caracterisation-Point-d-information. Accessed March 2014
  20. 20.
    Selçuk K, Gürdal Y, Ahmet K, Beriç E, Iftihar K. Treatment of Gram positive left sided infective endocarditis with daptomycin. J Infect Chemother. 2013;19(4):698–702.CrossRefGoogle Scholar
  21. 21.
    Kullar R, Casapao AM, Davis SL, Levine DP, Zhao JJ, Crank CW, et al. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother. 2013;68(12):2921–6.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC Jr, Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother. 2006;50(4):1581–5.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med. 2007;120(10):S13–20.CrossRefPubMedGoogle Scholar
  24. 24.
    Byren I, Rege S, Campanaro E, Yankelev S, Anastasiou D, Kuropatkin G, et al. Randomized controlled trial ofthe safety and efficacy of daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty. Antimicrob Agents Chemother. 2012;56(11):5626–32.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Pablo S, Perez-Cardona C, Barro Ojeda V, Rodriguez Pardo D, Pigrau Serrallach C. Clinical experience with daptomycin for the treatment of patients with knee and hip periprosthetic joint infections. J Antimicrob Chemother. 2012;67(7):1749–54.CrossRefGoogle Scholar
  26. 26.
    Liang SL, Khair HN, McDonald JR, Badcock HM, Marschall J. Daptomycin versus vancomycin for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA): a nested case-control study. Eur J Clin Microbiol Infect Dis. 2014;33(4):659–64.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Basseti M, Nicco E, Ginocchio F, Ansaldi F, De Florentiis D, Viscoli C. High-dose daptomycine in documented Staphylococcus aureus infections. Int J Antimicrob Agents. 2010;36(5):459–61.CrossRefGoogle Scholar
  28. 28.
    Dohmen PM, Guleri A, Capone A, Utili R, Seaton RA, González-Ramallo VJ, et al. Daptomycin for the treatment of infective endocarditis: results from a European registry. J Antimicrob Chemother. 2013;68(4):936–42.CrossRefPubMedGoogle Scholar
  29. 29.
    Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159–77.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing 2016

Authors and Affiliations

  • Camille Castel
    • 1
    Email author
  • Arnaud de La Blanchardière
    • 2
  • Jocelyn Michon
    • 2
  • Vincent Cattoir
    • 3
  • Guillaume Saint-Lorant
    • 1
  1. 1.Service de pharmaciecentre hospitalier universitaire de CaenCaen Cedex 9France
  2. 2.Service des maladies infectieusescentre hospitalier universitaire de CaenCaen Cedex 9France
  3. 3.Service de microbiologiecentre hospitalier universitaire de CaenCaen Cedex 9France

Personalised recommendations

Cite article

Buy options